2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2008
DOI: 10.1109/iembs.2008.4649708
|View full text |Cite
|
Sign up to set email alerts
|

A novel endoscopic delivery system for placement of a duodenal-jejunal implant for the treatment of obesity and type 2 diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2013
2013
2018
2018

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(12 citation statements)
references
References 7 publications
(6 reference statements)
0
12
0
Order By: Relevance
“…It will allow ingested foodstuffs to flow through; however, they will not make contact with digestive enzymes until they have passed the distal end of the sleeve [100]. An early randomized control study showed promise for the device, demonstrating a modest short-term weight loss (19 % excess weight loss) compared to control, as well as improvements in fasting glucose and HbA1c albeit only after 3 months of follow-up [101].…”
Section: Medical Devicesmentioning
confidence: 97%
“…It will allow ingested foodstuffs to flow through; however, they will not make contact with digestive enzymes until they have passed the distal end of the sleeve [100]. An early randomized control study showed promise for the device, demonstrating a modest short-term weight loss (19 % excess weight loss) compared to control, as well as improvements in fasting glucose and HbA1c albeit only after 3 months of follow-up [101].…”
Section: Medical Devicesmentioning
confidence: 97%
“…5) [41]. DJBS consists of a metallic anchor (Nitinol) that attaches the implant to the duodenum bulb and a 60 cm long GI liner that extends from duodenum to the proximal jejunum.…”
Section: Obesitymentioning
confidence: 99%
“…Pancreatic and bile secretions mix with the undigested nutrients at the distal end of the DJBL. The device is approved for a maximum treatment period of 12 months and is indicated for obese patients with T2DM …”
Section: Introductionmentioning
confidence: 99%